TP53 and cancer: The WES revealed that 5% of the lines were entirely heterozygous for a TP53 mutation associated with cancer and autosomal dominant inactivation of P53, and five of the lines carried six mutations in TP53. In over 60% of cases the mutations were mosaic and so might not be detected by limited sampling for quality control.